Hua S, de Matos MBC, Metselaar JM, Storm G (2018) Current trends and challenges in the clinical

translation of nanoparticulate nanomedicines: pathways for translational development and

commercialization. Front Pharmacol 9:790. https://doi.org/10.3389/fphar.2018.00790

Kamaly N, He JC, Ausiello DA, Farokhzad OC (2016) Nanomedicines for renal disease: current

status and future applications. Nat Rev Nephrol 12:738–753

Kandav G, Bhatt DC, Jindal DK (2019) Targeting kidneys by superparamagnetic allopurinol loaded

chitosan coated nanoparticles for the treatment of hyperuricemic nephrolithiasis. DARU J

Pharm Sci 27(2):661–671. https://doi.org/10.1007/s40199-019-00300-4

Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC (2012) Multifunctional nanoparticles for

multimodal imaging and theragnosis. Chem Soc Rev 41:2656

Lee SH, Lee JB, Bae MS, Balikov DA, Hwang A, Boire TC, Kwon PK, Sung PHJ, Yang JW (2015)

Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.

Adv Healthc Mater 4:2037–2045

Lin R, Wu R, Huang X, Xie T (2011) Immobilization of oxalate decarboxylase to Eupergit and

properties of the immobilized enzyme. Prep Biochem Biotechnol 41(2):154–165. https://doi.

org/10.1080/10826068.2011.547350

Lin R, He J, Wu J, Cai X, Long H, Chen S, Liu H (2017) Chemical modification of oxalate

decarboxylase to improve adsorption capacity. Int J Biol Macromol 98:495–501

Longmire MR, Ogawa M, Choyke PL, Kobayashi H (2014) Dendrimers as high relaxivity MR

contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 6:155. (PubMed: 24155241)

Maurya A, Singh AK, Mishra G, Kumari K, Rai A, Sharma B, Kulkerni GT, Awasthi R (2019)

Strategic use of nanotechnology in drug targeting and its consequences on human health: a

focused review. Interv Med Appl Sci 11:38–54. https://doi.org/10.1556/1646.11.2019.04

Mulens-Arias V, Rojas JM, Barber DF (2020) The intrinsic biological identities of iron oxide

nanoparticles

and

their

coatings:

unexplored

territory

for

combinatorial

therapies.

Nanomaterials 10:837. https://doi.org/10.3390/nano10050837

Pierzynowska K, Pierzynowski SG, Lozinska L, Jarmakiewicz S, Świeboda P, Fedkiv O, Szwiec K,

Piedra JLV, Filip R (2017) The influence of oxalate decarboxylase on the urinary oxalate

excretion in swine model of nephrocalcinosis induced by hydroxyproline. Eur J Clin Exp

Med 15:206–216

Rahman A, Likius D, Uahengo V, Iqbaluddin S (2017) A mini review highlights on the application

of nano-materials for kidney disease: a key development in medicinal therapy. Nephrol Renal

Dis 2(2):1–6. https://doi.org/10.15761/NRD.1000121

Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM (2005) Direct

fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc

127:10096–10100

Upadhyay RK (2017) Chronic kidney diseases and nanoparticle therapeutics. J Tissue Sci Eng 8:

209. https://doi.org/10.4172/2157-7552.1000209

Verma ML, Kumar P, Sharma S, Dhiman K, Sharma D, Verma A (2020) Gold nanoparticle-

mediated delivery of therapeutic enzymes for biomedical applications. In: Nanoscience in

medicine vol. 1, environmental chemistry for a sustainable world 39. Springer Nature

Switzerland AG. https://doi.org/10.1007/978-3-030-29207-2_3

Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med

63:185–198

Williams RM, Jaimes EA, Helle DA (2016) Nanomedicines for kidney diseases. Kidney Int 90(4):

740–745. https://doi.org/10.1016/j.kint.2016.03.041

Xu J, Wong DHC, Byrne JD, Chen K, Bowerman C, DeSimone JM (2013) Future of the particle

replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed 52:6580–6589

Zhao M, Xu D, Wu D, Whittaker JW, Terkeltaub R, Lu Y (2017) Nanocapsules of oxalate oxidase

for hyperoxaluria treatment. Nano Res 11(5):2682–2688. https://doi.org/10.1007/s12274-017-

1898-3

212

G. Shruti and K. S. Singh